tissu
transplant
therapi
utilis
year
rapidli
develop
field
carri
great
promis
amelior
cure
mani
diseas
one
drawback
howev
potenti
donortorecipi
diseas
transmiss
risk
greatli
reduc
exclud
donor
risk
carri
infect
test
donor
transmiss
infecti
diseas
asept
surgic
techniqu
qualiti
environ
remov
tissu
donor
process
store
tissu
implant
critic
import
prevent
bacteri
fungal
contamin
nonviabl
tissu
graft
bone
undergo
disinfect
sterilis
step
past
two
decad
diseas
transmiss
risk
associ
tissu
transplant
greatli
reduc
implement
standard
set
profession
organis
american
associ
tissu
bank
l
european
associ
tissu
bank
eatb
eye
bank
associ
america
l
government
regul
howev
incid
transplanttransmit
infect
unknown
studi
need
determin
perform
cadaver
donat
tabl
clinic
transplant
tabl
cornea
bone
skin
heart
valv
tissu
allograft
usa
greatli
exceed
organ
l
organ
transplant
flourish
earli
follow
discoveri
introduct
cyclosporin
effect
immun
suppress
brought
larg
suppli
cadaver
donor
avail
could
also
use
tissu
donat
unlik
limit
organ
transplant
tissu
transplant
gener
limit
hla
histocompat
barrier
l
abo
blood
group
incompat
sj
longer
scarc
resourc
widen
avail
tissu
allograft
encourag
new
clinic
use
brought
attent
effect
advantag
autograft
also
drawback
side
effect
complic
one
complic
tissu
transplant
transmiss
viral
infect
donor
origin
recipi
viral
infect
transmit
donor
viral
infect
viral
level
low
detect
asymptomat
donor
recent
infect
transient
virem
phase
exist
prior
develop
posit
donorscreen
test
antibodi
prevent
donortorecipi
infecti
diseas
transmiss
reli
heavili
select
safe
donor
test
also
medic
social
behaviour
screen
select
donor
like
free
transmiss
infect
addit
sterilis
gamma
irradi
import
tissu
allograft
eg
cornea
heart
valv
skin
need
remain
viabl
expos
disinfect
sterilis
without
unaccept
loss
viabil
graft
nonviabl
larg
compris
acellular
connect
tissu
disinfect
sterilis
freeli
result
greater
assur
steril
tabl
review
focus
viral
infect
transmit
transplant
tissu
step
taken
prevent
failur
transmit
viral
infect
hepat
b
surfac
antigen
hbsag
posit
donor
report
two
recipi
cornea
suggest
cornea
ineffici
mode
ofhbv
transmiss
although
case
administr
hepat
b
immun
globulin
vaccin
recipi
may
prevent
infect
khalil
eta
assess
presenc
ofhbsag
hbv
dna
corneal
button
taken
hbsagposit
donor
found
hbv
small
percentag
cornea
other
studi
donor
infect
hbv
hcv
unabl
detect
hbv
dna
hcv
rna
cornea
despit
ineffici
hbv
transmiss
corneal
transplant
report
earlier
review
oday
raber
friedman
brief
report
hepat
b
transmiss
cornea
recipi
hbsag
posit
donor
two
case
recipi
hbv
infect
transplant
two
differ
hbsagposit
donor
eventu
report
corneal
donat
took
place
two
donor
one
alcohol
man
one
inject
drug
user
test
hbv
perform
donor
retrospect
recipi
develop
hbv
infect
donor
posit
hbsag
one
two
recipi
cornea
two
donor
develop
symptomat
hbv
infect
use
current
profession
standard
feder
regul
would
prevent
case
sinc
exclus
donor
hepat
risk
behaviour
test
hbsag
requir
rabi
viru
infect
human
often
found
cornea
cornea
impress
test
use
earli
diagnosi
corneal
allograft
also
capabl
transmit
rabi
seven
case
fatal
rabi
transmiss
cornea
transplant
rej
ort
us
franc
thailand
india
iran
first
case
involv
man
us
ascend
paralysi
second
involv
donor
franc
die
paraplegia
enceph
myocard
javadi
eta
gode
bhide
report
rabi
develop
two
patient
receiv
corneal
transplant
donor
cadaver
donor
obviou
acut
neurolog
ill
clinic
consist
rabi
nation
profession
standard
use
tissu
bank
today
prohibit
use
donor
would
prevent
case
rabi
transmiss
cytomegaloviru
appear
readili
transmit
cornea
transplant
seroposit
cadaver
donor
seroneg
recipi
seroneg
patient
receiv
corneal
graft
seroposit
donor
two
seroconvert
herp
simplex
viru
type
found
widespread
corneal
stromal
cell
one
case
transmiss
cornea
allograft
report
infect
caus
corneal
deterior
recipi
fifth
day
transplant
hsv
dna
found
two
five
cornea
allograft
donor
hepat
report
use
unprocess
refriger
frozen
bone
allograft
bone
graft
clean
cell
fat
water
jet
ethanol
soak
prior
freez
dri
treat
steril
gamma
irradi
ethylen
oxid
prior
avail
viral
hepat
test
donor
yale
medic
student
receiv
refriger
bone
graft
treat
depress
fractur
proxim
tibia
develop
hepat
jaundic
week
later
bone
graft
obtain
amput
leg
patient
occlus
vascular
diseas
gangren
otherwis
donor
good
health
normal
liver
function
test
without
histori
jaundic
liver
diseas
donor
receiv
blood
transfus
year
previous
three
report
nearli
decad
ago
document
hepat
c
viru
hcv
transmit
donortorecipi
use
frozen
unprocess
bone
allograft
first
case
donor
test
hcv
antibodi
avail
hcv
transmit
use
femor
head
allograft
donat
donor
undergo
hip
arthroplasti
store
frozen
month
second
report
hcv
transmit
infect
cadaver
tissu
donor
frozen
unprocess
bone
tendon
graft
freezedri
bone
allograft
treat
gamma
irradi
studi
cadav
bone
donor
test
neg
hcv
antibodi
use
first
gener
test
avail
time
donat
store
serum
test
posit
new
sensit
test
introduc
test
hcv
rna
polymeras
chain
reaction
pcr
also
posit
third
brief
report
involv
five
hcvinfect
organ
tissu
cadaver
donor
minor
recipi
frozen
bone
allograft
becam
infect
hcv
recent
case
hcvinfect
organ
tissu
donor
test
found
neg
hcv
antibodi
despit
neg
screen
test
hcv
sever
organ
tissu
recipi
becam
infect
blood
sampl
donor
test
later
hcv
rna
result
posit
confirm
link
donor
multipl
infect
recipi
donor
recent
infect
virem
yet
produc
detect
antibo
iie
bone
allograft
donor
treat
gamma
irradi
transmit
hcv
implement
ofhcv
rna
donorscreen
test
futur
case
would
prevent
report
hbv
transmiss
bone
transplant
although
recognis
complic
organ
cornea
heart
valv
transplant
quit
probabl
transmiss
none
recognis
publish
transmit
blood
tissu
organ
viabl
recov
bone
marrow
tendon
patient
acquir
immunodefici
syndrom
fatal
infect
transmit
woman
undergo
spinal
fusion
scoliosi
use
frozen
femor
head
allograft
sever
week
donat
hip
arthroplasti
donor
histori
intraven
drug
abus
enlarg
lymph
node
biopsi
previou
year
donor
bone
allograft
recipi
subsequ
die
aid
test
antibodi
avail
time
donat
donor
would
elig
donor
today
due
histori
intraven
drug
abus
lymphadenopathi
case
oflllv
infect
recipi
bone
allograft
deriv
hivinfect
donor
test
hiv
time
donat
prior
hiv
antibodi
test
avail
germani
recipi
frozen
bone
alloraft
infect
cadaver
donor
novemb
januari
four
recipi
becam
hiv
posit
seven
remain
hivneg
taiwan
man
donat
femor
head
hip
replac
surgeri
test
mv
bone
allograft
use
woman
knee
reconstruct
surgeri
seroconvert
lllv
antibodi
test
five
month
later
anoth
report
case
lllv
transmiss
use
frozen
bone
allograft
involv
seroneg
infect
cadaver
donor
test
new
veg
sensit
multipl
organ
cornea
bone
connect
tissu
transplant
three
organ
recipi
three
recipi
frozen
bone
tendon
allograft
becam
hiv
infect
allograft
sterilis
gamma
irradi
ethylen
oxid
ga
prior
use
donor
test
neg
hiv
antibodi
time
donat
octob
month
first
rel
insensit
hiv
antibodi
test
kit
becam
avail
sever
modif
greatli
improv
test
sensit
prior
hiv
antibodi
detect
median
day
initi
infect
studi
hiv
infect
blood
donor
march
whole
viral
lysat
enzym
immunoassay
use
detect
hiv
antibodi
show
averag
seroneg
window
period
day
report
show
hiv
antibodi
test
kit
use
time
detect
twice
mani
infect
individu
test
kit
avail
sinc
lllv
antibodi
test
becam
even
sensit
detect
igm
earliest
form
antibodi
averag
day
earlier
result
seroneg
window
period
approxim
day
sinc
blood
donor
test
hiv
rna
nucleic
acid
test
nat
implement
reduc
risk
transfus
valid
implement
cadav
tissu
donor
reduc
risk
tissu
transplant
preval
hiv
antibodi
bone
donor
low
medic
histori
screen
select
process
appli
vigor
greatli
differ
voluntari
blood
donor
may
true
live
bone
donor
rs
necessarili
cadaver
donor
live
bone
donor
donat
femor
head
time
hip
arthroplasti
surgeri
none
found
confirm
posit
test
hiv
antibodi
time
donat
j
preval
infecti
diseas
marker
surgic
bone
donor
differ
blood
donor
except
higher
preval
fals
posit
syphili
test
antibodi
hbv
core
protein
retest
livin
bone
donor
day
later
yield
none
confirm
posit
hiv
hcv
test
cadav
bone
donor
test
throughout
unit
state
three
confirm
posit
hiv
antibodi
three
singl
tissu
bank
later
disclos
accept
donor
risk
factor
hiv
recent
survey
aatb
reveal
higher
preval
rate
infecti
diseas
marker
report
blood
donor
rate
rang
time
higher
tabl
addit
viral
nucleic
acid
test
sinc
screen
blood
donor
hiv
hcv
reduc
risk
blood
donor
first
time
blood
donor
hiher
infecti
diseas
marker
rate
may
similar
organ
tissu
donor
prospect
tissu
donor
hiv
risk
behaviour
posit
test
hiv
exclud
bone
graft
process
remov
blood
marrow
cell
appli
disinfect
steril
risk
ofhiv
transmiss
bone
transplant
remot
nearli
absent
risk
transmittinf
hiv
bone
graft
calcul
less
one
million
graft
even
less
graft
subject
process
sterilis
step
use
gamma
irradi
ethylen
oxid
howev
hiv
transmiss
risk
higher
less
frequent
use
frozen
unprocess
bone
allograft
accur
estim
risk
made
accur
determin
preval
ofhiv
infect
donor
recipi
popul
avail
prospect
studi
done
recipi
human
tlymphotroph
viru
asymptomat
htlvi
infect
transmit
transplant
freshfrozen
unprocess
femor
head
bone
allograft
man
becam
infect
htl
v
blood
transfus
hip
surgeri
one
month
later
develop
fever
rash
transient
rightsid
radial
nerv
palsi
frozen
sera
obtain
ill
test
later
demonstr
htl
v
seroconvers
donat
femor
head
without
antihtl
v
test
second
surgeri
hip
prosthesi
unprocess
frozen
femor
head
use
graft
differ
patient
one
month
later
bone
graft
recipi
develop
htlvi
antibodi
htlvi
associ
diseas
costal
cartilag
allograft
routin
disinfect
sterilis
prior
use
allograft
provid
freezedri
frozen
form
report
process
costal
cartilag
transmit
infect
donor
recipi
donald
cole
survey
surgeon
use
cartilag
allograft
preserv
differ
method
facial
reconstruct
surgeri
found
postop
bacteri
infect
rate
similar
report
follow
use
autolog
cartilag
use
patellar
tendon
allograft
replac
knee
injur
anterior
cruciat
ligament
becom
commonplac
hiv
isol
tendon
hiv
infect
person
transmit
seroneg
cadaver
tissu
donor
donat
patellar
tendon
use
knee
surgeri
hcv
transmit
recipi
frozen
tendon
allograft
antihcv
posit
cadaver
donor
possibl
hiv
hcv
harbour
unprocess
bone
block
either
end
tendon
allograft
allograft
process
remov
blood
marrow
cell
despit
case
risk
recipi
presum
low
long
donorscreenin
step
appli
requir
nation
standard
feder
regul
addit
tendon
treat
gamma
irradi
reduc
risk
diseas
transmiss
select
donor
without
risk
factor
without
hcv
antibodi
make
risk
spread
hcv
transplant
exceedingli
rare
event
howev
earli
hcv
infect
cadaver
organ
tissu
donor
yet
produc
antibodi
report
recent
patellar
tendon
allograft
recipi
develop
acut
symptomat
hepat
c
may
six
week
transplant
potenti
sourc
infect
identifi
tissu
donor
antihcv
neg
store
serum
show
hcv
rna
test
later
thirtynin
person
receiv
tissu
organ
donor
earli
result
partial
complet
investig
show
recipi
test
six
show
hcv
infect
includ
lung
recipi
becam
hcv
rna
posit
day
die
liver
failur
month
later
presum
cadaver
donor
virem
stage
earli
infect
prior
antibodi
develop
date
cadaver
test
hcv
rna
avail
routin
use
hcv
rna
consid
cadaver
tissu
donor
soon
test
reliabl
evalu
particularli
use
cadaver
sampl
obtain
hour
death
capac
human
heart
valv
allograft
transmit
hbv
demonstr
studi
thirtyon
patient
receiv
heart
valv
allograft
hbsagposit
donor
twentytwo
recipi
hbsagposit
prior
transplant
immun
hbv
suscept
hbv
infect
fu
addit
found
antihbc
fiftytwo
donor
antihbc
also
antibodi
hbv
surfac
protein
antihb
indic
resolv
hbv
infect
recov
immun
noninfecti
statu
three
antihbc
without
antihb
posit
hbv
dna
use
sensit
liquidphas
dna
hybridis
assay
would
suggest
possibl
valu
antihbc
donor
test
prevent
transmiss
hbv
howev
one
studi
blood
donor
shown
lack
predict
valu
prevent
posttransfus
hepat
recent
howev
sever
report
confirm
antihbc
posit
donor
posit
dna
transmit
hbv
recent
case
illi
infect
transmit
use
saphen
vein
allograft
report
cadaver
donor
known
hlv
risk
factor
sign
hepat
neg
test
mv
antibodi
subsequ
studi
demonstr
hcv
rna
donor
serum
serotyp
found
donor
result
donor
test
known
skin
use
author
report
whether
recipi
risk
factor
present
result
confirm
test
hlv
transmiss
skin
allograft
recent
review
transmiss
hepat
skin
allograft
report
although
hcv
nucleic
acid
demonstr
skin
infect
donor
recent
report
impli
transmiss
human
cytomegaloviru
cmv
anim
model
clearli
demonstr
skin
graft
capabl
transmit
cmv
earlier
studi
kealey
et
al
show
bum
patient
acquir
cmv
hospitalis
blood
transfus
may
contribut
factor
subsequ
studi
elimin
blood
transfus
contributor
studi
patient
receiv
skin
allograft
cmvposit
blood
show
cmvneg
bum
patient
receiv
skin
allograft
cmvposit
donor
seroconvert
becom
cmvposit
cmv
resid
peripher
blood
leukocyt
asymptomat
cmv
antibodyposit
donor
long
initi
infect
asymptomat
cmv
posit
donor
transmit
cmv
infect
transfus
transplant
recipi
cmv
neg
healthi
adult
prospect
donor
cmv
antibodi
therefor
exclud
cmv
posit
donor
prevent
cmv
transmiss
would
exacerb
alreadi
exist
shortag
skin
allograft
would
practic
test
donor
cmv
antibodi
requir
nation
profession
standard
immunosuppress
individu
organ
recipi
high
mortal
morbid
rate
transplanttransmittedcmv
donor
origin
burn
patient
also
acquir
cmv
infect
gener
experi
seriou
complic
regularli
organ
recipi
perhap
burnrel
immunosuppress
may
less
profound
produc
drug
use
prevent
organ
reject
burn
patient
begin
receiv
potent
immunosuppress
cyclosporin
block
reject
skin
allograft
cmv
may
becom
seriou
complic
burn
care
relat
blood
transfus
skin
allograft
studi
skin
allograft
recipi
need
determin
whether
transmiss
cmv
skin
allograft
associ
symptomat
diseas
seen
organ
transplant
recipi
asymptomat
gener
seen
transfusiontransmit
cmv
infect
immunocompet
blood
transfus
recipi
thu
prematur
assum
benefici
base
select
skin
donor
cmv
antibodi
test
addit
mosquitoborn
wnv
transmit
organ
transplant
blood
transfus
transplacent
intrauterin
spread
percutan
rout
lacer
needlestick
new
corona
viru
infect
recent
caus
sever
acut
respiratori
syndrom
sar
spread
across
contin
although
suscept
virus
gamma
irradi
steril
unknown
routin
use
sterilis
may
provid
protect
transmiss
tissu
transplant
minimis
risk
transmit
viral
infecti
diseas
sever
import
approach
taken
transplant
surgeon
tissu
bank
initi
approach
surgeon
judici
use
tissu
allograft
need
accredit
organis
use
sterilis
allograft
whenev
possibl
consid
use
autograft
altern
nonhuman
graft
materi
howev
import
step
exercis
tissu
bank
exclud
prospect
donor
known
suspect
viral
infect
suspect
behaviour
risk
hiv
hepat
tabl
tissu
transplant
gener
consid
nonurg
surgic
procedur
permit
care
tissu
donor
select
process
tissu
donor
select
tissu
bank
evolv
includ
direct
interview
donor
nextofkin
concern
donor
medic
histori
risk
behaviour
hlv
hepat
along
blood
infecti
diseas
test
physic
examin
result
autopsi
examin
perform
tabl
donor
select
step
essenti
activ
result
low
risk
transmit
virus
addit
mani
tissu
allograft
undergo
process
exposur
disinfect
steril
reduc
hazard
diseas
transmiss
although
care
control
studi
allograft
recipi
determin
incid
diseas
transmiss
good
reason
believ
establish
donor
screen
procedur
infecti
diseas
test
process
sterilis
effect
reduc
elimin
virus
result
low
risk
transmit
diseas
one
import
contribut
recipi
safeti
seek
voluntari
nonremuner
donor
monetari
induc
nextofkin
cadaver
tissu
donor
prohibit
profession
standard
consid
mean
reduc
sever
organ
suppli
shortag
us
monetari
payment
donor
blood
donat
increas
risk
diseas
transmiss
monetari
incent
donat
may
caus
donor
next
kin
untruth
donor
health
histori
inform
donat
publish
data
clearli
show
time
increas
incid
donortorecipi
posttransfus
hepat
b
viru
infect
use
paid
blood
donor
addit
time
increas
preval
ofhcv
antibodi
time
increas
preval
ofhiv
antibodi
paid
blood
donor
compar
voluntari
blood
donor
hcv
rna
detect
often
clot
factor
concentr
deriv
paid
donor
plasma
volunt
donor
plasma
minimis
risk
transmit
infecti
diseas
tissu
donor
elig
requir
set
nation
profession
standard
us
public
health
servic
guidelin
us
feder
regul
donor
select
import
first
step
taken
ensur
result
allograft
safe
effect
cadav
tissu
donor
select
process
includ
donor
medic
social
histori
obtain
nextofkin
medic
care
provid
blood
test
physic
examin
perform
tissu
bank
personnel
autopsi
perform
tabl
preliminari
donor
select
base
donor
medic
histori
circumst
surround
death
donor
exclud
element
past
medic
social
histori
recent
hospitalis
indic
risk
infect
malign
diseas
inadequ
qualiti
donat
organ
tissu
live
donor
legal
consent
nextofkin
life
partner
cadaver
donor
must
directli
interview
determin
whether
idv
hepat
risk
behaviour
present
tabl
person
lllv
hepat
risk
behaviour
exclud
donat
tissu
bank
physician
make
final
determin
suitabl
cadaver
tissu
donor
requir
nation
profession
standard
next
screen
step
limit
physic
examin
tissu
donor
procur
staff
time
cadaver
donat
bodi
examin
sign
inject
drug
use
sign
oflllv
hepat
infect
trauma
bodili
site
affect
qualiti
donat
tissu
donor
blood
test
diseas
marker
play
import
role
reduc
risk
diseas
transmiss
elimin
prospect
donor
infecti
diseas
risk
factor
prior
blood
test
risk
seroneg
infect
donor
minimis
test
hbsag
antiidv
antihcv
requir
feder
regul
nation
profession
standard
set
organ
test
requir
standard
set
organ
syphili
antihtlvil
idv
antigen
antigen
test
donor
perform
tissu
organ
bank
largescal
studi
low
risk
j
high
risk
blood
donor
popul
demonstr
lack
util
idv
antigen
screen
blood
donor
studi
similar
studi
smaller
number
cadav
bone
cornea
donor
detect
hiv
infect
donor
beyond
alreadi
detect
test
lllv
antibodi
howev
region
world
may
higher
preval
oflllv
infect
popul
idv
antigen
test
may
use
especi
lllv
rna
test
perform
one
tissu
bank
report
find
bone
donor
neg
test
idv
antibodi
posit
test
lllv
antigen
presum
idv
antigen
test
fals
posit
bone
bank
ad
precaut
treat
bone
allograft
mrad
gamma
irradi
l
l
studi
underway
determin
whether
test
donor
idv
rna
hcv
rna
nucleic
acid
test
practic
one
studi
cadav
bone
donor
show
use
oflllv
dna
lllv
rna
antigen
blood
test
detect
addit
illi
infect
cadaver
bone
donor
lojj
donor
neg
antibodi
also
neg
lllv
dna
expect
sinc
appear
idv
dna
recent
infect
person
blood
occur
sooner
onset
detect
antibodi
hand
lllv
rna
appear
earlier
greater
potenti
benefit
although
hiv
rna
test
sensit
antibodi
assay
may
prematur
appli
routin
cadav
donor
test
due
low
hiv
preval
donor
popul
uncertain
predict
valu
fals
posit
rate
fals
neg
rate
due
haemoglobin
contamin
potenti
interf
substanc
cadaver
postmortem
blood
sampl
test
live
blood
donor
hiv
hcv
rna
markedli
improv
safeti
blood
suppli
even
though
screen
done
use
pool
sampl
rssj
initi
viral
nucleic
acid
test
feasibl
blood
donor
screen
applic
due
lack
autom
time
space
restrict
cost
recent
howev
test
system
use
test
million
blood
donat
annual
unit
state
roch
molecular
system
coba
ampliscreen
test
hcv
hiv
genprobechiron
pool
plasma
amplifi
assay
test
done
pool
sampl
use
pool
test
pool
sampl
reduc
number
test
requir
daili
basi
time
perform
test
cost
also
take
account
rapid
rise
viral
rna
recent
infect
individu
pool
minim
impact
sensit
assay
increas
sensit
system
previous
avail
pcr
test
also
made
possibl
system
licens
blood
donor
screen
effort
underway
qualifi
organ
tissu
donor
screen
approach
test
trial
hbv
wnv
mani
bone
bank
test
donor
antihbc
test
origin
introduc
blood
donor
surrog
detect
nona
nonb
hepat
carrier
util
test
surrog
diminish
sinc
ad
specif
test
hcv
hcv
antibodi
hcv
rna
major
caus
nona
nonb
hepat
although
requir
aatb
standard
absenc
ofhbv
dna
test
use
antihbc
donor
test
like
safeti
benefit
reduc
hbv
infect
sever
report
document
presenc
hbv
sera
hbsagneg
antihbcposit
blood
donor
report
also
suggest
addit
hbv
dna
test
increas
sensit
hbv
detect
may
entir
replac
need
test
antihbc
hbsag
exampl
recipi
direct
lookback
procedur
reveal
recipi
hbsag
neg
nat
neg
anti
hbcposit
blood
compon
infect
hbv
f
l
massiv
blood
loss
intravascular
volum
replac
transfus
blood
colloid
crystalloid
solut
caus
hemodilut
result
unreli
donor
test
result
infecti
diseas
iosj
case
report
ofhiv
transmiss
multipl
recipi
organ
deriv
infect
donor
test
donor
neg
blood
sampl
immedi
receiv
blood
transfus
amount
two
three
total
blood
volum
addit
larg
volum
crystalloid
solut
elevenhour
period
blood
sampl
obtain
hour
later
test
antihiv
posit
due
intravascular
replenish
immunoglobulin
extravascular
site
us
feder
regul
f
jj
first
publish
subsequ
modif
requir
quarantin
tissu
adult
donor
blood
loss
receiv
greater
two
litr
blood
colloid
within
hour
blood
sampl
greater
one
litr
crystalloid
within
one
hour
sampl
donat
tissu
use
unless
pretransfus
sampl
avail
test
algorithm
use
evalu
blood
colloid
volum
administ
hour
prior
sampl
ensur
suffici
plasma
dilut
alter
test
result
occur
aatb
standard
also
requir
tissu
bank
follow
written
procedur
set
hemodilut
limit
prevent
use
fals
neg
result
test
posttransfus
blood
sampl
infecti
diseas
accept
limit
must
part
written
procedur
standard
american
red
cross
tissu
servic
requir
case
blood
loss
transfus
within
hour
death
preinfus
sampl
must
use
postinfus
sampl
may
use
patient
major
clinic
blood
loss
provid
tissu
bank
physician
evalu
whether
blood
crystalloid
infus
compens
blood
loss
estim
hemodilut
percent
less
total
blood
volum
tissu
bank
physician
give
written
approv
estim
amount
hemodilut
depend
upon
type
fluid
infus
amount
time
elaps
sinc
infus
test
cadaver
tissu
donor
serum
viral
marker
may
complic
fals
posit
test
sampl
delay
death
haemolysi
fals
posit
result
hbsag
antigen
due
haemolysi
may
found
depend
upon
manufactur
test
kit
use
sampl
qualiti
presenc
haemoglobin
also
caus
fals
neg
result
test
idv
hcv
nat
iio
lllj
frozen
storag
multipl
freezethaw
major
effect
detect
antibodi
infecti
agent
serum
may
reduc
reliabl
test
microbi
nucleic
acid
nat
busch
et
al
show
multipl
freez
thaw
reduc
detect
hcv
rna
nat
publish
studi
draw
firm
conclus
possibl
deleteri
effect
frozen
storag
freez
thaw
test
serum
hcv
rna
peripher
blood
white
cell
ffiv
dna
nat
despit
nat
use
detect
retrospect
diagnos
hiv
infect
use
marrow
specimen
organ
tissu
donor
frozen
sera
organ
recipi
year
donat
transplant
hcv
test
nat
also
use
confirm
hcv
infect
one
cadaver
donor
essenti
anoth
although
nat
hepat
idv
use
test
develop
organ
tissu
donor
test
autopsi
donor
gener
requir
tissu
store
final
donor
suitabl
determin
made
tissu
bank
physician
result
autopsi
perform
review
z
j
autopsi
find
may
reliabl
detect
viral
infect
result
disqualifi
donor
undiagnos
malign
widespread
granuloma
abscess
pneumonia
femor
head
donat
person
undergo
hip
arthroplasti
donor
medic
histori
screen
test
requir
similar
cadav
bone
donor
except
donor
medic
histori
interview
made
directli
retest
idv
hcv
antibodi
requir
day
follow
donat
retest
aim
identifi
recent
infect
donor
seroneg
idv
hcv
antibodi
time
donat
day
retest
requir
semen
bone
donor
live
donor
blood
marrow
amnion
umbil
vein
foetal
tissu
retest
low
risk
voluntari
live
bone
donor
detect
addit
infect
despit
thousand
donat
retest
wherea
may
util
higher
risk
popul
paid
semen
donor
tissu
bank
ceas
collect
surgic
femor
head
partli
due
lower
qualiti
also
due
difficulti
acquir
sampl
retest
test
sampl
hcv
mv
rna
live
donor
time
donat
would
enhanc
safeti
could
elimin
need
retest
tissu
allograft
contamin
bacteria
fungu
process
environ
surfac
air
personnel
contamin
reagent
surgic
instrument
suppli
process
equip
case
mv
hcv
transmiss
tissu
allograft
origin
viru
infect
donor
electrolyt
solut
purchas
commerci
deionis
water
prepar
tissu
bank
contamin
bacteria
contamin
tissu
allograft
use
process
rare
case
hbv
contamin
acquir
liquid
nitrogen
storag
led
widespread
practic
use
vapour
phase
rather
submers
liquid
phase
viral
contamin
tissu
process
report
bone
graft
disinfect
sterilis
step
often
use
bone
bank
unit
state
gamma
irradi
dose
kgi
sever
type
tissu
process
step
involv
elimin
blood
cell
exposur
disinfect
alcohol
peroxid
viral
inactiv
properti
use
steril
gamma
irradi
ethylen
oxid
heat
reliabl
erad
viabl
virus
transplant
tissu
result
transmit
viral
diseas
donor
recipi
first
truli
effect
immunosuppress
cyclosporin
becam
avail
organ
transplant
flourish
number
organ
transplant
year
grew
rapidli
lead
implement
effect
program
develop
public
support
organ
donat
organ
donat
grew
tissu
donat
rapid
growth
transplant
earli
case
transplant
transmit
viral
diseas
aros
infect
donor
could
prevent
test
avail
use
new
sensit
donor
viral
detect
test
reduc
risk
recipi
infect
earli
case
transmit
viral
infect
involv
donor
mv
hepat
risk
behaviour
exclus
prospect
donor
play
import
role
reduc
risk
transmiss
recent
sever
case
report
infect
organ
bacteri
fungal
instead
viral
microb
aris
donor
contamin
acquir
procur
process
storag
tissu
newer
nation
profession
standard
us
fda
regul
address
area
prevent
least
minimis
risk
transmiss
infecti
diseas
sever
approach
import
surgeon
use
allograft
need
obtain
accredit
tissu
bank
consid
use
autograft
altern
nonhuman
graft
materi
process
sterilis
tissu
allograft
whenev
possibl
tissu
bank
reduc
risk
reject
donor
suspect
risk
hiv
hepat
viral
bacteri
infect
perform
donor
physic
examin
review
autopsi
report
surgic
remov
donat
tissu
use
asept
techniqu
lastli
sterilis
certain
tissu
effect
univers
applic
virus
rel
resist
steril
clinic
effect
mani
tissu
skin
cornea
valv
vein
alter
sterilis
procedur
applic
step
assur
low
risk
transmit
diseas
donor
recipi
